News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ADMA Biologics, Inc. Reports Second Quarter 2014 Financial And Operational Results



8/12/2014 8:37:22 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

RAMSEY, N.J.--(BUSINESS WIRE)--ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today reported its financial and operational results for the second quarter ended June 30, 2014 and announced recent company developments and anticipated milestones for 2014.

“During the second quarter, we continued our clinical development progress for RI-002”, stated Adam Grossman, ADMA Biologics’ President and Chief Executive Officer. “About one half of patients enrolled in the pivotal Phase III trial in PIDD have completed all scheduled study visits and more than 90% of the infusions of RI-002 have been administered. Importantly, there have been no reported serious adverse events attributable to the study drug to date. We are on schedule to report preliminary Phase III data in Q4 2014.”

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES